Non-Small Cell Lung Cancer Coverage from Every Angle

Recent News

EMERGING-CTONG 1103 Trial: Neoadjuvant Erlotinib in EGFR-Mutant Lung Cancer
Entrectinib Approved by FDA for ROS1-Positive NSCLC
Two-Drug Combination Targets Resistance in Cancer
Early Results With Dual Inhibition of VEGFR2 and PD-1 in Advanced Lung Cancer
Can Lower Radiation Doses Reduce Damage to Immune System and Improve Outcomes in NSCLC?
Pemetrexed/Carboplatin/Gefitinib: New Standard of Care for Untreated EGFR-Mutant Lung Cancer?
A Risk Prediction Model For Patients With Lung Nodules
Adjuvant Therapy for Completely Resected Advanced Nonsquamous NSCLC
RET Inhibitor Shows Activity in Select Patients With Lung Cancer in ARROW Trial
FDA Approves Bevacizumab Biosimilar in Nonsquamous NSCLC
ASCO 2019: Dual EGFR and VEGFR Blockade in Metastatic Lung Cancer
ASCO 2019: Interim Results With Neoadjuvant Atezolizumab in Resectable Lung Cancer
ASCO 2019: Proton Therapy Versus Conventional Photon Therapy in Locally Advanced Cancer
ASCO 2019: Comparing Maintenance Therapies for Nonsquamous Lung Cancer
ASCO 2019: Neoadjuvant Combination Checkpoint Blockade in Early-Stage NSCLC
ASCO 2019: Long-Term Survival With Pembrolizumab for Advanced NSCLC
ASCO 2019: Expanding Traditional Clinical Trial Eligibility in NSCLC
Predicting the Course of Lung Cancer in Situ
Pooled Analysis of Use of Entrectinib in ROS1-Positive Lung Cancer
Lung Cancer Organizations Launch Collaborative Foundation for Lung Cancer Community
ELCC 2019: Does Age Affect Toxicity in Immunotherapy-Treated Patients With NSCLC?
ELCC 2019: Patient-Reported Outcomes With Durvalumab in NSCLC
Can Clinical Use of Capsaicin Slow the Spread of Lung Adenocarcinoma?
ELCC 2019: First-Line Treatment With Osimertinib in Advanced EGFR -Mutant NSCLC
ELCC 2019: Larotrectinib in TRK Fusion–Positive Lung Cancer
AACR 2019: Savolitinib Plus Osimertinib in EGFR -Mutant, MET-Amplified NSCLC
ELCC 2019: Pembrolizumab Monotherapy in Elderly Patients With Advanced NSCLC
HOPA 2019: Flat-Dose Nivolumab Dosing in First-Line Treatment of NSCLC
FDA Expands Pembrolizumab Indication in First-Line Treatment of NSCLC
Novel Approach to Predicting Adverse and Beneficial Effects of Immunologic Interventions
Role for Oxoglutarate Carrier in Formation of Lung Cancer
Less Frequent Dosing of Nivolumab in NSCLC
STS 2019: Identifying Candidates for Adjuvant Therapy for Early-Stage Lung Adenocarcinoma
STS 2019: Can Mutations Predict Survival After Pulmonary Metastasectomy for Colorectal Cancer?
Thoracic Cancers Symposium 2019: Evidence-Based Decision-Making in NSCLC
ASCO-SITC 2019: Predicting Response to Immunotherapy in NSCLC
Thoracic Cancers Symposium 2019: Local Consolidative Therapy for Oligometastatic NSCLC
AACR 2019: Clinical Utility of Cell-Free DNA Liquid Biopsy in Metastatic Lung Cancer
2019 ASCO-SITC Symposium: Neoadjuvant Atezolizumab in NSCLC
2019 ESMO TAT: Predicting Outcomes With Lung Immune Prognostic Index
2019 ASCO-SITC Symposium: Vaccine Plus Nivolumab in Lung Cancer
FDA Grants Priority Review for Entrectinib in ROS1-Positive NSCLC

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.